These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2402040)

  • 1. The association of cyclosporine with the 1-year costs of cadaver-donor kidney transplants.
    Showstack J; Katz P; Amend W; Salvatierra O
    JAMA; 1990 Oct; 264(14):1818-23. PubMed ID: 2402040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cyclosporine on the use of hospital resources for kidney transplantation.
    Showstack J; Katz P; Amend W; Bernstein L; Lipton H; O'Leary M; Bindman A; Salvatierra O
    N Engl J Med; 1989 Oct; 321(16):1086-92. PubMed ID: 2507916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual trends and triple therapy--1991-2000.
    Nishikawa K; Terasaki PI
    Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney retransplantation in the cyclosporine era.
    Stratta RJ; Oh CS; Sollinger HW; Pirsch JD; Kalayoglu M; Belzer FO
    Transplantation; 1988 Jan; 45(1):40-5. PubMed ID: 3276060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A third kidney transplant: cost-effective treatment for end-stage renal disease?
    Matas AJ; Gillingham KJ; Payne WD; Dunn DL; Gruessner RW; Sutherland DE; Schmidt W; Najarian JS
    Clin Transplant; 1996 Dec; 10(6 Pt 1):516-20. PubMed ID: 8996772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal transplantation at the University of Pennsylvania Medical Center: an update of results in the cyclosporine era.
    Brayman KL; Egidi FM; Naji A; Friedman AL; Perloff L; Grossman R; Zmijewski CM; Cameron E; Kobrin S; Feldman H
    Clin Transpl; 1992; ():215-25. PubMed ID: 1306700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic costs of expanded criteria donors in renal transplantation.
    Whiting JF; Golconda M; Smith R; O'Brien S; First MR; Alexander JW
    Transplantation; 1998 Jan; 65(2):204-7. PubMed ID: 9458015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for prolonged hospitalization after kidney transplants.
    Matas AJ; Gillingham KJ; Elick BA; Dunn DL; Gruessner RW; Payne WD; Sutherland DE; Najarian JS
    Clin Transplant; 1997 Aug; 11(4):259-64. PubMed ID: 9267712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in living donor graft rates by dialysis clinic: effect on outcome and cost of chronic renal failure therapy.
    Baltzan MA; Ahmed S; Baltzan RB; Marshall RP; Thoma EL; Nicol MF
    Clin Nephrol; 1997 Jun; 47(6):351-5. PubMed ID: 9202863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs.
    Gjertson DW; Terasaki PI; Takemoto S; Mickey MR
    N Engl J Med; 1991 Apr; 324(15):1032-6. PubMed ID: 2005940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The UNOS renal transplant registry.
    Cecka JM
    Clin Transpl; 2001; ():1-18. PubMed ID: 12211771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The UNOS Scientific Renal Transplant Registry--ten years of kidney transplants.
    Cecka JM
    Clin Transpl; 1997; ():1-14. PubMed ID: 9919387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients.
    Abou-Jaoude MM; Najm R; Shaheen J; Nawfal N; Abboud S; Alhabash M; Darwish M; Mulhem A; Ojjeh A; Almawi WY
    Transplant Proc; 2005 Sep; 37(7):3025-8. PubMed ID: 16213293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LifeLink Foundation and cadaver kidney transplantation in Tampa.
    LeFor WM; Wright CE; Bowers VD; Heinrichs DF; Shires DL
    Clin Transpl; 1999; ():149-58. PubMed ID: 11038633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The UNOS Scientific Renal Transplant Registry.
    Cecka JM
    Clin Transpl; 1999; ():1-21. PubMed ID: 11038622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacoeconomics of renal transplantation: increased drug costs with decreased hospitalization costs.
    Canafax DM; Gruber SA; Chan GL; Miles CJ; Matas AJ; Najarian JS; Cipolle RJ
    Pharmacotherapy; 1990; 10(3):205-10. PubMed ID: 2371142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New law of renal transplantation in Portugal associated with more acute rejection episodes and higher costs.
    Gonçalves JA; Jorge C; Atalaia A; Matias P; Bruges M; Birne R; Dickson J; Weigert A; Machado D
    Transplant Proc; 2012 Oct; 44(8):2276-9. PubMed ID: 23026572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
    Thistlethwaite JR; Heffron TG; Stuart JK; Buckingham M; Stuart FP
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
    Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS
    Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term results with elective cyclosporine withdrawal at three months after renal transplantation--appropriate for living-related transplants.
    Kahn D; Ovnat A; Pontin AR; Swanepoel CR; Cassidy MJ
    Transplantation; 1994 Dec; 58(12):1410-2. PubMed ID: 7809935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.